Sign Up
OverviewAPI
Multiple law firms have initiated class action lawsuits against bluebird bio, Inc. for allegedly making false statements about FDA approvals, resulting in significant stock price drops. The lawsuits claim misleading statements about gene therapy drugs for sickle cell disease and violations of securities laws, leading to investor damages.

Ask a question